Recent Updates
Recently added Catalysts
HCM Neutral Sentiment

2025 Annual Report and Notice of Annual General

Key Takeaway: HUTCHMED (China) Limited announced that its 2025 Annual Report and related AGM materials will be posted on April 10, 2026, for shareholders opting for printed versions. The upcoming 2026 Annual General Meeting is scheduled for May 12, 2026, at the Harbour Grand Kowloon in Hong Kong, available through an electronic platform for those unable to attend in person. HUTCHMED focuses on developing targeted therapies and immunotherapies for cancer and immunological diseases, with its products already marketed in various regions.
Price reaction · baseline $14.98 (2026-04-08 close) · hit after-hours · clean, no other HCM news in the window
day 0 close · peak
+1.2%

Market Sentiment Analysis

Full Press Release Details

2025 Annual Report and Notice of Annual General
Hong Kong, Shanghai & Florham Park,
NJ - Thursday, April 9, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:
HCM; HKEX: 13) today announces that its 2025 Annual Report, together with the Notice of Annual General Meeting and the Form of Proxy
("AGM Materials"), will be posted on April 10, 2026 to those shareholders who have elected to receive the AGM Materials
in printed form. The documents can also be accessed from the HUTCHMED website (www.hutch-med.com).
The 2026 Annual General Meeting ("AGM")
will be an electronic/hybrid meeting to be held at 1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom, Kowloon, Hong Kong
on Tuesday, May 12, 2026 at 4:00 pm Hong Kong Time (9:00 am London Time), with electronic access through an online platform as detailed
in the AGM Materials.
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug
candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which
is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com
Investor Enquiries +852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting - +44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper +44 7771 913 902 (Mobile) / +44 7779 436 689 (Mobile)
Brunswick - Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden +44 20 7886 2500
Cavendish Joint Broker
Geoff Nash / Nigel Birks +44 20 7220 0500
Deutsche Numis Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith +44 20 7260 1000

Frequently Asked Questions

When will the 2025 Annual Report be posted?

The 2025 Annual Report will be posted on April 10, 2026.

What is the date and time of the 2026 AGM?

The 2026 AGM is on May 12, 2026, at 4:00 pm Hong Kong Time.

How can shareholders access the AGM Materials?

Shareholders can access AGM Materials on the HUTCHMED website or in printed form.

Where will the 2026 AGM be held?

The 2026 AGM will be at Harbour Grand Kowloon in Hong Kong.

What is HUTCHMED's focus as a biopharmaceutical company?

HUTCHMED focuses on developing targeted therapies and immunotherapies for cancer.

Last updated: Apr 9, 2026